A Phase 1/2 Study of High-dose Genetically Targeted Enzyme Replacement Therapy for Advanced Heart Failure

Clinical trial NCT02346422 · TERMINATED

Trial details

NCT number: NCT02346422
Sponsor: Celladon Corporation
Status: TERMINATED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Ischemic Cardiomyopathy Non-ischemic Cardiomyopathy Heart Failure Cardiomyopathies

Start date: 2015-04-01
Primary completion: 2015-06-26
Enrollment: 9

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.